Safely Delivered Targeted High-dose Irradiation Followed by Adoptive Immunotherapy with Regulatory and Conventional T Cells to Increase Potency of Hematopoietic Stem Cell Transplantation in High-risk Acute Leukemia

Recruiting N/A Interventional Study
Acute Myeloid Leukaemia (AML) Acute Lymphoblastic Leukemia ALL High Risk Leukaemia Leukaemia Relapse
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 65
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
51 (estimated)
Sponsor
University Of Perugia · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The study is a monocentric, interventional study that evaluates the efficacy of allogeneic HLA-matched or haploidentical transplantation consisting of an irradiation-based conditioning regimen coupled with donor Treg/Tcon adoptive immunotherapy for high-risk acute leukemia patients.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * AML patients * Diagnosis of AML with indication to allogeneic hematopoietic cell transplantation. * Diagnosis of adverse genetic risk leukemia or presence of MRD or active disease (bone marrow infiltration 5-30%) at the time of the transplant procedure. * Availability o…
Contacts

Antonio Pierini

+393355477611

antonio.pierini@unipg.it

CONTACT

Loredana Ruggeri

+393388953982

loredana.ruggeri@ospedale.perugia.it

CONTACT